FiercePharma

Sandoz launches donepezil HCL tablets, a generic version of Aricept®

Princeton, New Jersey; June 1, 2011 - Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of donepezil hydrochloride (HCL) film-coated tablets and donepezil HCL ...
Nasdaq

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Monthly Prescribing Reference

Adlarity Once-Weekly Patch Now Available for Alzheimer Dementia

The patch was approved in March 2022 based on a relative bioavailability study in healthy patients comparing the transdermal system to Aricept tablets. Adlarity ®, a once-weekly patch that delivers ...
Medscape

FDA Approves High-Dose Donepezil for Advanced Alzheimer's Disease

July 27, 2010 — The US Food and Drug Administration (FDA) has approved donepezil HCl 23-mg tablets (Aricept; Eisai, Inc and Pfizer, Inc) for the once-daily treatment of moderate to severe Alzheimer's ...
FiercePharma

Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval For New Higher-Dose Aricept® (Donepezil HCl) 23 mg Tablet

Woodcliff Lake, NJ, and New York, July 23, 2010 - Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept ...
Monthly Prescribing Reference

Donepezil Transdermal Patch Approved for Alzheimer Disease

Credit: Shutterstock. Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. The Food and Drug Administration (FDA) has ...